Breast Removal Surgery: Understanding the Procedure, Reasons, and Recovery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Mastectomy (breast removal surgery) is the surgical excision of all breast tissue from one or both breasts. It is most commonly performed as a primary treatment for breast cancer, but is also performed prophylactically (risk-reducing mastectomy) in women with high hereditary breast cancer risk — particularly BRCA1 and BRCA2 gene mutation carriers — and as gender-affirming chest masculinisation surgery in trans men (bilateral mastectomy with male chest contour). The decision to undergo mastectomy, the type of mastectomy, and the simultaneous versus staged reconstruction options are among the most significant medical and personal decisions a patient will face.

Modern breast surgery has evolved substantially from the radical Halsted mastectomy of the early 20th century — which removed the breast, both pectoral muscles, and all axillary lymph nodes, causing significant deformity and disability — to the current range of skin-sparing, nipple-sparing, and muscle-preserving mastectomies that minimise tissue loss while achieving oncological safety and enabling superior reconstructive outcomes. The goal of contemporary mastectomy is to remove all breast tissue while preserving as much overlying skin, the inframammary fold, and ideally the nipple-areola complex as oncologically appropriate.

Mastectomy is performed under general anaesthesia as part of a comprehensive oncological surgical plan. For breast cancer, the operation includes assessment or surgical treatment of the regional lymph nodes (sentinel lymph node biopsy in clinically node-negative disease; full axillary node clearance when node involvement is confirmed). Breast reconstruction — using implants or autologous tissue — can be initiated at the same operation (immediate reconstruction) or at a later date (delayed reconstruction).

The multidisciplinary breast team — including breast surgeons, oncoplastic surgeons, medical and radiation oncologists, radiologists, pathologists, breast cancer nurses, and clinical psychologists — discuss each case in a tumour board setting to determine the optimal surgical and adjuvant treatment plan. Patients are central to this decision-making process; informed consent must encompass a thorough understanding of alternative treatments (breast-conserving surgery where appropriate), reconstruction options, adjuvant therapy implications, and the expected functional and psychological impact.

Therapeutic mastectomy is the primary treatment for breast cancer when breast-conserving surgery (lumpectomy) is not feasible or preferred — including: tumours too large relative to breast size for adequate margin excision with acceptable cosmesis; multifocal or multicentric breast cancer (tumours in multiple separate areas); inflammatory breast cancer; when radiotherapy (required after lumpectomy) is contraindicated; locally advanced disease requiring mastectomy for local control; recurrent breast cancer after previous lumpectomy and radiotherapy; and patient preference for mastectomy over breast conservation.

Prophylactic risk-reducing bilateral mastectomy is performed in women with BRCA1 or BRCA2 gene mutations (lifetime breast cancer risk 55-85%), women with other high-penetrance mutations (PALB2, CHEK2, ATM), those with a strong family history meeting risk thresholds, and women with prior chest radiotherapy (Hodgkin's lymphoma treatment) who have very high lifetime risk. Bilateral risk-reducing mastectomy reduces breast cancer risk by over 90% in BRCA carriers. Chest masculinisation (bilateral mastectomy with male chest contouring) is performed for gender dysphoria in trans men and gender-non-conforming individuals seeking a flat, masculine chest. All mastectomy types may include sentinel lymph node biopsy for staging, though this is unnecessary for purely prophylactic procedures.

Mastectomy eligibility is determined by clinical indication. For therapeutic mastectomy, any patient with a breast cancer diagnosis requiring mastectomy based on tumour and patient factors is a candidate; the primary medical eligibility consideration is fitness for general anaesthesia and the associated procedure. Comorbidities are managed to optimise surgical risk where possible. Systemic fitness and the oncological priority of surgery means most breast cancer patients with mastectomy indication proceed to surgery.

For risk-reducing mastectomy, genetic testing results, risk calculation (Tyrer-Cuzick or BOADICEA model), specialist genetics or high-risk breast clinic assessment, and typically a minimum 3-6 month period of psychological preparation and informed decision-making are prerequisites. Most centres require the patient to have completed childbearing discussions and to have made an informed autonomous decision after thorough counselling. For gender-affirming mastectomy, eligibility follows WPATH Standards of Care — typically requiring a gender dysphoria diagnosis, psychological readiness assessment, and in some systems a period of living in the affirmed gender role, though requirements vary internationally.

Total (simple) mastectomy removes all breast tissue including the nipple-areola complex (NAC), typically through an elliptical incision across the breast, leaving a flat chest. This is the standard approach for therapeutic mastectomy without skin preservation. Skin-sparing mastectomy (SSM) removes all breast tissue and the NAC but preserves the breast skin envelope through a periareolar incision — providing an ideal skin shell for immediate breast reconstruction with the most natural aesthetic result. Nipple-sparing mastectomy (NSM) preserves both the skin and the NAC through incisions placed in the inframammary fold, lateral breast, or periareolar position — providing the best cosmetic outcome when the nipple is not involved by tumour and is oncologically safe. The risk of nipple involvement by cancer is excluded by frozen section or planned biopsies of the subareolar tissue.

Modified radical mastectomy removes the breast and axillary lymph nodes while preserving both pectoral muscles. Robot-assisted and endoscopic mastectomy approaches (performed through remote access incisions, avoiding the traditional breast scar) are technically feasible at specialist centres and particularly appealing for nipple-sparing mastectomy, though evidence of long-term oncological equivalence continues to accumulate. Bilateral mastectomy (simultaneous removal of both breasts) for prophylactic or bilateral cancer indications has increased significantly in recent years. The mastectomy can be immediately followed by breast reconstruction (direct-to-implant or tissue expander, or autologous flap) at the same anaesthetic, or reconstruction can be deferred.

For therapeutic breast cancer mastectomy, the primary benefit is achieving local control of the cancer — eliminating detectable local disease and reducing local recurrence risk. In appropriately selected cases, mastectomy and breast-conserving surgery with radiotherapy are oncologically equivalent in terms of overall survival and distant disease-free survival (confirmed by 20-year follow-up data from multiple randomised trials). Mastectomy provides lower local recurrence risk (typically less than 5% at 10 years versus 10-15% after lumpectomy without radiotherapy), which is particularly important in the context of specific tumour biology or patient inability to receive radiotherapy.

For risk-reducing bilateral mastectomy in BRCA1/2 carriers, the procedure reduces breast cancer risk by over 90%, providing a degree of risk reduction that no screening programme can match. This benefit must be weighed against the irreversible nature of the procedure and the psychosocial and physical implications of breast loss. Prophylactic mastectomy with immediate reconstruction enables women at very high genetic risk to significantly reduce their cancer risk while preserving their body image and quality of life through reconstruction. Studies demonstrate that the majority of BRCA carriers who undergo prophylactic mastectomy with reconstruction do not regret the decision and report reduced cancer-related anxiety.

Mastectomy itself has a relatively low immediate surgical complication rate in the absence of reconstruction: wound infection (2-3%), haematoma (1-3%), seroma under the mastectomy skin flap (20-40% — typically managed by aspiration), and skin flap necrosis in patients with diabetes, smoking history, or tight closure. Axillary surgery — whether sentinel node biopsy or full clearance — carries additional risks: lymphoedema (arm swelling) in less than 5% after sentinel biopsy and 15-20% after full clearance; nerve injury (intercostobrachial nerve causing upper arm numbness — very common, usually improves); and limited shoulder mobility requiring physiotherapy.

Nipple-sparing mastectomy carries a risk of nipple-areola complex (NAC) necrosis — ischaemia of the preserved nipple and areola — occurring in 5-10% of cases and requiring NAC excision. This risk is higher in patients with a long skin flap distance between the incision and the nipple, in smokers, and in patients with diabetes. When immediate reconstruction is performed, complications of the reconstruction add to the total risk profile (see breast reconstruction guide). Psychological impact — loss of the natural breast, altered body image, and fear of cancer recurrence — is significant and should be addressed through pre-operative counselling and access to psychological support services.

Recovery from mastectomy alone (without reconstruction) is relatively rapid: hospital stay 1-2 days; removal of surgical drains at 1-3 days when drainage is minimal; return to light activities at 2-3 weeks; and full recovery at 4-6 weeks. The mastectomy wound site should be assessed at one week for wound healing and at two weeks for discussion of histological results. Physiotherapy exercises for shoulder and arm mobility begin in hospital and continue at home.

Adjuvant therapies following mastectomy are prescribed based on histological findings: radiotherapy to the chest wall and nodal regions in patients with involved lymph nodes or large tumours; chemotherapy for HER2-positive, triple-negative, or high-risk hormone receptor-positive cancers; targeted therapy (trastuzumab for HER2+); and endocrine therapy (tamoxifen, aromatase inhibitor) for hormone receptor-positive cancers for 5-10 years. Oncological follow-up continues annually with clinical examination and mammography of the remaining breast (in unilateral mastectomy) for at least 5 years. Genetic counselling and cascade testing of family members are offered to patients with confirmed hereditary gene mutations.

In the USA, therapeutic mastectomy costs USD 15,000-30,000 including the surgical team, anaesthesia, hospitalisation, and pathology. With immediate implant reconstruction, total costs reach USD 25,000-45,000; with DIEP flap reconstruction, USD 50,000-80,000. These costs are covered by insurance for cancer diagnoses, and the WHCRA mandates coverage for reconstruction. Risk-reducing mastectomy for BRCA carriers is also typically covered by insurance when genetic testing confirms high-risk mutation. In the UK, NHS covers all medically indicated mastectomies and reconstructions without patient cost.

For patients seeking mastectomy abroad at internationally accredited oncology centres, costs are dramatically lower while maintaining equivalent care quality. In India (Tata Memorial Hospital, Apollo Cancer Centre), therapeutic mastectomy with immediate implant reconstruction costs USD 4,000-8,000; with DIEP flap reconstruction USD 10,000-18,000 — savings of 60-80% versus US private rates. Thailand's leading cancer hospitals (Bumrungrad International, Vejthani Hospital) offer mastectomy packages at USD 5,000-12,000. Patients travelling for breast cancer surgery should ensure the centre has a dedicated multidisciplinary breast tumour board, full adjuvant therapy capabilities, and internationally certified pathology for sample review.

For most early breast cancers (Stage I-II), breast-conserving surgery (lumpectomy) followed by adjuvant radiotherapy is the alternative to mastectomy with equivalent survival outcomes. The choice between mastectomy and lumpectomy is influenced by tumour-to-breast ratio, tumour biology, patient preference, ability to receive radiotherapy, and the availability of oncoplastic techniques to achieve margins with acceptable cosmesis. Patients with large tumours relative to breast size may achieve downstaging through neoadjuvant chemotherapy, allowing breast-conserving surgery that would otherwise have required mastectomy.

For BRCA carriers who decide against prophylactic mastectomy, intensive surveillance (annual breast MRI from age 25, with alternating mammography) combined with chemoprevention (tamoxifen or raloxifene to reduce risk) is the alternative risk management strategy. This does not reduce cancer risk as dramatically as surgery but is an appropriate choice for women who prefer to preserve their breasts. For trans men seeking chest masculinisation, the only alternative to bilateral mastectomy is ongoing chest binding — which is physically restrictive, carries long-term skin and musculoskeletal consequences, and does not address gender dysphoria to the same degree as surgery.